India, April 12 -- Telix Pharmaceuticals Limited (TLX,TLX.AX) and Regeneron Pharmaceuticals, Inc. (REGN) have announced a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies. This partnership brings together Telix's radiopharmaceutical development platform, global manufacturing capabilities, and supply chain infrastructure with Regeneron's biologics expertise, including bispecific antibody discovery. The collaboration will focus on multiple solid tumor targets from Regeneron's antibody portfolio, generated using VelocImmune(R) mice. In addition, both companies plan to develop radio-diagnostics to aid patient selection and treatment response assessment, reinforcing their shared commitment to preci...